INTEGRA LIFESCIENCES HOLDINGS CORP
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.6B | $1.6B | $1.5B | $1.6B | $1.5B |
| Cost of revenue | $803.6M | $728.5M | $656.8M | $587.4M | $597.8M |
| Selling, general & administrative | $699.7M | $717.0M | $656.6M | $616.3M | $637.4M |
| Research and development | $99.0M | $115.4M | $104.2M | $101.2M | $93.1M |
| Operating income | -$493.4M | $28.4M | $111.5M | $238.9M | $197.2M |
| Interest expense | $86.3M | $70.6M | $51.4M | $49.6M | $50.4M |
| Pretax income | -$563.5M | -$18.2M | $81.1M | $213.9M | $214.7M |
| Income tax expense | -$47.0M | -$11.3M | $13.3M | $33.3M | $45.6M |
| Net income | -$516.5M | -$6.9M | $67.7M | $180.6M | $169.1M |
| Balance Sheet | |||||
| Cash and equivalents | $235.0M | $246.4M | $276.4M | $456.7M | $513.4M |
| Current assets | $1.2B | $1.1B | $1.1B | $1.2B | $1.2B |
| Total assets | $3.6B | $4.0B | $3.8B | $3.9B | $3.8B |
| Current liabilities | $456.0M | $922.1M | $307.0M | $320.9M | $340.0M |
| Total liabilities | $2.6B | $2.5B | $2.2B | $2.1B | $2.1B |
| Stockholders' equity | $1.0B | $1.5B | $1.6B | $1.8B | $1.7B |
| Cash Flow Statement | |||||
| Cash from operations | $50.4M | $129.4M | $140.0M | $264.5M | $312.4M |
| Depreciation and amortization | $44.8M | $42.4M | $40.9M | $40.1M | $39.4M |
| Stock-based compensation | $18.6M | $24.4M | $20.1M | $27.7M | $36.2M |
| Capital expenditure | $81.4M | $104.4M | $66.9M | $42.3M | $48.0M |
| Free cash flow | -$31.1M | $25.0M | $73.1M | $222.1M | $264.4M |
| Share repurchases | $221,000 | $52.5M | $275.0M | $125.0M | $0 |
| Impairments | $511.4M | $0 | $0 | $0 | $2.8M |
Shares outstanding 77.8M · Free float 98.0%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.